Skip to search formSkip to main contentSkip to account menu

MK 0752

Known as: MK-0752, MK0752, Notch Signaling Pathway Inhibitor MK0752 
A synthetic small molecule with potential antineoplastic activity. MK0752 inhibits the Notch signaling pathway, which may result in induction of… 
National Institutes of Health

Related topics

Related topics

1 relation
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
A phase I trial of the c-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma
Natalie Cook*, Bristi Basu, Donna-Michelle Smith, Aarthi Gopinathan, Jeffry Evans, William P Steward, Daniel Palmer, David… 
2015
2015
Abstract S4-03: Identification of a notch-driven breast cancer stem cell gene signature for anti-notch therapy in an ER+ presurgical window model
Background: Resistance to endocrine therapy (ET; tamoxifen or aromatase inhibitors, AI) for ER+ breast cancer is a major cause of… 
2013
2013
Has inhibition of Aβ production adequately been tested as therapeutic approach in mild AD? A model-based meta-analysis of γ-secretase inhibitor data
To date, γ-secretase inhibition is the most frequently studied mechanism of reducing Aβ in clinical trials with as yet no… 
2012
2012
A novel Phase I/IIa design for early phase oncology studies and its application in the evaluation of MK‐0752 in pancreatic cancer
The Cancer Research UK study CR0720‐11 is a trial to determine the tolerability and effect on survival of using two agents in… 
Review
2012
Review
2012
Advances in molecular targets for the treatment of medulloblastomas.
PURPOSE To present an assortment of molecular targets evident from a variety of signal transduction pathways and downstream… 
2012
2012
Moving forward one Notch at a time.
In the articles that accompany this editorial, Tolcher et al and Krop et al report the results of two phase I studies that… 
Highly Cited
2010
Highly Cited
2010
Acute γ-Secretase Inhibition of Nonhuman Primate CNS Shifts Amyloid Precursor Protein (APP) Metabolism from Amyloid-β Production to Alternative APP Fragments without Amyloid-β Rebound
The accumulation of amyloid β (Aβ) in Alzheimer's disease is caused by an imbalance of production and clearance, which leads to… 
2010
2010
Abstract P6-15-03: Phase Ib Trial of the Gamma Secretase Inhibitor (GSI), MK-0752 Followed by Docetaxel in Locally Advanced or Metastatic Breast Cancer
Background: The cancer stem cell hypothesis asserts that there is a small population of cells within a tumor that has the ability… 
2010
2010
A phase I trial of MK-0752 in children with recurrent or refractory CNS malignancies: A Pediatric Brain Tumor Consortium study.
9502 Background: The NOTCH pathway plays a central role in normal neural stem cell regulation and maintenance. Recent data… 
Review
2008
Review
2008
Recent progress in the medicinal chemistry of gamma-secretase inhibitors.
Abeta is implicated in the initiation and progression of Alzheimer's disease (AD) by the phenotypic analysis of mutations in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)